HSP90AA1 and neoplasm: Thus the synergistic effects in tumor regression observed in animal studies after the combinatorial administration of Hsp90 inhibitors and potent anti-cancer drugs hold true in human trials, hence targeted combination therapies hold potential for future drug designing.